“Any suggestion that our commitment to continued investment in global health has reduced, is fundamentally untrue,” Dr. Thomas Breuer, the company’s chief global health officer, wrote in a statement.
The company told ProPublica […] that a vaccine for TB is radically different from the company’s other vaccines because it can’t be sold at scale in wealthy countries.
This is the best summary I could come up with. I am not a bot ;-)
As other comments have pointed out, I’m not convinced the premise of your question is correct. I’ll throw in Slimbook to increase the sample size: